Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 14/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 3/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17681745 | 0.86 | UCHL1 (0.38) | GHSRUCHL1CYP3A4HTR1ADRD1 | |
| SCHEMBL22180581 | 0.86 | UCHL1 (0.38) | GHSRUCHL1CYP3A4HTR1ADRD1 | |
| SCHEMBL24529009 | 0.86 | UCHL1 (0.39) | GHSRUCHL1GPR119CYP3A4HTR1A | |
| SCHEMBL24528950 | 0.84 | ALDH1A1 (0.47) | GHSRUCHL1CYP3A4HTR1ADRD1 | |
| SCHEMBL30878494 | 0.84 | UCHL1 (0.40) | GHSRUCHL1CYP3A4HTR1ADRD1 | |
| SCHEMBL18794436 | 0.81 | UCHL1 (0.41) | GHSRUCHL1CYP3A4HTR1ADRD1 | |
| SCHEMBL17681686 | 0.81 | UCHL1 (0.41) | GHSRUCHL1CYP3A4HTR1ADRD1 | |
| SCHEMBL24528905 | 0.81 | UCHL1 (0.38) | GHSRUCHL1CYP3A4HTR1ADRD1 | |
| SCHEMBL24528738 | 0.81 | GHSR (0.42) | GHSR | |
| SCHEMBL30828046 | 0.81 | GHSR (0.42) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115711-A1 | Novel Bifunctional Molecules For Targeted Protein Degradation | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-04-11 | — | — | US | disclosed |
| EP-4263511-A1 | NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | Amphista Therapeutics Ltd (GB) | 2023-10-25 | — | — | EP | disclosed |
| CN-116897150-A | Novel bifunctional molecules for protein-targeted degradation | 安菲斯塔治疗有限公司 | 2023-10-17 | — | — | CN | disclosed |
| WO-2022129925-A1 | NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022129925-A1 | NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115711-A1 | Novel Bifunctional Molecules For Targeted Protein Degradation | PSMG3, MYCBP2, PSME2 | GHSR 4309/4885UCHL1 289/4885GPR119 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.